



Date: May 28, 2026

To,

Asst. General Manager,
Dept. of Corporate Services,
BSE Limited
1st Floor, P.J. Towers,
Dalal Street, Fort,
Mumbai: 400001.

Sub: Outcome of the Board Meeting held on Thursday, May 28, 2026.
Reference: CLINITECH LABORATORY LIMITED (CTLLAB) Scrip Code: 544220.

With reference to the above captioned subject, we wish to intimate your esteemed exchange that as decided in the Meeting of the Board of Directors of the Company held today, i.e., on May, 28, 2026, for which intimation was already given to you, the Board of Directors has:

1. considered and approved the Audited Standalone & Consolidated Financial Results of the Company along with Auditor's Report for the half year and financial year ended March 31, 2026;
2. taken note of Internal Audit Report for the half year ended March 31, 2026;
3. taken note of related party transactions during the year ended March 31, 2026 and approved the estimated related party transactions to be held for FY 2026-27.

Pursuant to Regulation 33 of SEBI (listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the declaration regarding audit report with "unmodified opinion" as '*Annexure - I*'

In connection with Point No. 1, please find enclosed the copy of Audited standalone & consolidated financial Results of the Company along with Auditor's Report for the half year and financial year ended March 31, 2026 by the Statutory Auditors of the Company as "*Annexure-II*" and copy of certificate indicating the utilization of the issue proceeds certified by Statutory Auditor as required pursuant to circular no. NSE/CML/2024/23 as '*Annexure - III*'

The meeting of Board of Directors held today at 02.30 P.M (IST) and concluded at 02.45 P.M (IST).

Thanking you,


Yours faithfully,

For CLINITECH LABORATORY LIMITED

Jagdish Umakant Nayak
Chairman and Managing Director

DIN: 00646672

Encl: as above



Clinitech Laboratory Limited

CIN-L85195MH2010PLC201078

Annexure I

Declaration regarding audit report with “unmodified opinion” on Standalone & Consolidated Financial Results as on March 31, 2026

(Pursuant to Regulation 33 of SEBI (listing Obligations and Disclosure Requirements) Regulations, 2015)

With reference to the above stated subject and pursuant to Regulation 33 of SEBI (listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby declare that the Audit report issued for the financial year ended March 31, 2026 by M/s Kale Malde & Co., Chartered Accountants (Firm Registration Number 0154422W), Statutory Auditors of the Company contains with “**unmodified opinion**” on Audited Standalone & Consolidated Financial Statements & Financial Results which is attached herewith for your reference.

Kindly consider the same and take a note of this declaration in your records.

Thanking you,

Yours faithfully,

For CLINITECH LABORATORY LIMITED

Jagdish Umakant Nayak
Chairman and Managing Director
DIN: 00646672

Head Office : AL 1 545/546, sec. 16 Airoli, Opp. Radhikabai Meghe Vidyalaya, Navi Mumbai - 400 708

Tel. : 022 45003240, 8828222580, Website : www.ctllab.in

E-mail : clinitechlaboratorypvt@gmail.com

Refer to conditions of reporting overleaf

Independent Auditor's Report on Half yearly and Yearly Standalone Financial Results of the CLINITECH LABORATORY LIMITED (Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended))

INDEPENDENT AUDITOR'S REPORT

To,
The Board of Directors of
CLINITECH LABORATORY LIMITED

Opinion

We have audited the accompanying half yearly and yearly Standalone Financial results ('the Statement') of **CLINITECH LABORATORY LIMITED ('the Company')** for the half year and year ended on 31st March, 2026 and year to date results for the period from April 01, 2025 to March 31, 2026 prepared and being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended (The 'Listing Regulations').

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid Standalone Financial statements

- a) are presented in accordance with the requirements of Regulation 33 of the Regulations; and
- b) give the information required by the Companies Act, 2013 ("the Act") in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2026, and net profit and other financial information for the year ended on 31st March, 2026.

Basis for Opinion

We conducted our audit of the Standalone Financial statements in accordance with the Standards on Auditing ("SAs") specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial statements section of our report.

We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the Standalone Financial statements under the



provisions of the Companies Act, 2013 and the Rules there under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Standalone Financial statements

Management's Responsibility for Standalone Financial Results

This statement, is the responsibility of the Company's Management and approved by the Board of Directors has been compiled the basis of Standalone Financial statements for the year ended 31 March, 2026. The Company's Board of Directors are responsible for the preparation and presentation of the Financial Results that gives true and fair view of the net profit and other comprehensive income and other financial information in accordance with the accounting principles generally accepted in India, including the accounting Standards specified under section 133 of the Act and in compliance with Regulation 33 of the listing Regulations.

This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Standalone Financial statements, The Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of



assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists.

Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. But not for the purpose of expressing an opinion on the effectiveness of such controls.
- Evaluate the appropriateness and reasonableness of disclosures made by Board of Directors in the term of the requirement specified under Regulation 33 of the Listing Regulation.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Standalone Financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial Results, including the disclosures and whether the financial Results represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the Financial Results of the Company to Express an Opinion on the Financial Results.

Materiality is the magnitude of misstatements in the Financial Results that, individually or in aggregate, makes it probable that the economic decisions of are reasonably



knowledgeable user of the Financial Results may be influenced. We consider quantitative materiality and qualitative factors in –

1. Planning the scope of our audit work and in evaluating the results of our work; and
2. To evaluate the effect of any identified misstatements in the Financial Results.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matters

The Annual Standalone Financial Results dealt with by this report have been prepared for the express purpose of filing with Stock Exchanges. These results are based on and should be read with the audited Standalone Financial statements of the Company for the year ended 31st March 2026 on which we issued an unmodified audit opinion.

The result includes the results of the half year ended 31st March, 2026 being the balancing figure between the audited figure in respect of the full financial year ended 31st March, 2026 and the unaudited year –to-date figures up to the first half ended on 30th Sep, 2025 of the current financial year which were subject to a limited review by us, as required under the Listing Regulations.

For Kale Malde & Co.

Chartered Accountants
FRN: 154422W



CA. Alpesh Malde
Partner

Membership No. 138034

Place: Dombivli

Date: 28/05/2026

ICAI UDIN: **26138034CRITYXP4415**



CLINITECH LABORATORY LIMITED

CIN : L85195MH2010PLC201078


Audited Standalone Balance Sheet as at 31st March, 2026

All amounts in Lakhs, unless otherwise stated

Particulars	As at March 31, 2026	As at March 31, 2025
I. EQUITY AND LIABILITIES		
Shareholders' funds		
Share capital	228.24	228.24
Reserves and Surplus	697.05	654.80
	925.29	883.04
Non-current liabilities		
Long-Term Borrowings	35.76	-
Long-Term Provisions	25.34	19.87
	61.10	19.87
Current liabilities		
Trade Payables		
total outstanding dues of micro and small enterprises	26.40	69.74
total outstanding dues of creditors other than micro and small enterprises	13.55	5.76
Other current liabilities	43.44	74.45
Short-Term Provisions	21.61	31.14
	105.00	181.09
TOTAL EQUITY AND LIABILITIES	1091.39	1084.00
II. ASSETS		
Non-current assets		
Property, Plant and Equipment and Intangible Assets		
Property, Plant and Equipment	214.35	211.92
Intangible assets	3.99	0.39
Intangible Assets under development	99.12	101.12
Non-current investments	8.49	7.29
Other Non-current assets	9.18	-
Deferred Tax Assets (Net)	19.92	16.65
	355.05	337.37
Current assets		
Inventories	73.05	52.87
Trade Receivables	184.68	154.10
Cash and Cash Equivalents	206.46	307.48
Short-term loans and advances	69.53	73.15
Other current assets	202.62	159.03
	736.34	746.63
TOTAL ASSETS	1091.39	1084.00

As per our report of even date

For Kale Malde & Co.
Chartered Accountants
FRN: 154422W



A. Alpesh Malde
Partner

Membership No: 138034
Date: 28/05/2026
Place: Dombivli

ICAI UDIN: 26138034CRXYXP4415



For and on behalf of the Board of Directors of
CLINITECH LABORATORY LIMITED


Jagdish Umakant Nayak
Chairman & Managing Director
DIN : 00646672
Date: 28/05/2026
Place: Navi Mumbai



CLINITECH LABORATORY LIMITED

CIN : L85195MH2010PLC201078

Audited Standalone Financial Results for the Half Year and Year ended 31st March, 2026

All amounts in INR Lakhs, unless otherwise stated

Particulars	Half year Ended on			Year Ended on	
	31-Mar-26	30-Sep-25	31-Mar-25	31-Mar-26	31-Mar-25
	Audited	Unaudited	Audited	Audited	Audited
A] REVENUE					
Revenue from operations	439.48	508.02	415.89	947.50	823.49
Other income	7.81	11.00	17.38	18.81	22.77
B] Total Income	447.29	519.02	433.27	966.31	846.26
C] Expenses:					
Cost of materials consumed	87.25	137.76	75.23	225.01	155.93
Laboratory Testing Charges	14.21	17.43	14.38	31.64	27.33
Employee benefits expense	151.18	157.18	145.29	308.36	286.14
Finance costs	2.18	4.74	1.79	6.92	5.51
Depreciation and Amortization Expense	25.99	25.05	13.76	51.04	44.98
Other Expenses	141.17	141.78	153.30	282.96	270.90
D] Total expenses	421.98	483.94	403.75	905.93	790.79
E] Profit before tax	25.31	35.08	29.52	60.38	55.47
F] Tax expense:					
(1) Current tax	11.55	4.68	11.31	16.23	15.96
(2) Excess/(Short) Provision of Income tax	5.17	-	-	5.17	-
(3) Deferred tax	-3.64	0.37	0.84	-3.27	0.04
G] Total Tax Expenses	13.08	5.05	12.15	18.13	16.00
H] Profit/(Loss) After Tax [E - G]	12.23	30.03	17.37	42.25	39.47
Earning per equity share:					
Face value per equity shares Rs.10/- fully paid up.					
(1) Basic	0.59	1.32	0.83	1.85	1.90
(2) Diluted	0.59	1.32	0.83	1.85	1.90

As per our report of even date


For Kale Malde & Co.
Chartered Accountants
FRN: 154422W


CA. Alpesh Malde
Partner

Membership No: 138034
Date: 28/05/2026
Place: Dombivli
ICAI UDIN:26138034CRXYXP4415



For & On Behalf of the Board
CLINITECH LABORATORY LIMITED


Jagdish Nayak
Chairman and Managing Director
DIN : 00646672
Date: 28/05/2026
Place: Navi Mumbai



CLINITECH LABORATORY LIMITED

CIN : L85195MH2010PLC201078

Audited Standalone Statement of Cash Flows for the year ended 31st March, 2026

All amounts in Lakhs, unless otherwise stated

Particulars	Year ended March 31, 2026	Year ended March 31, 2025
A. CASH FLOW FROM OPERATING ACTIVITIES		
Profit before tax	60.38	55.47
Adjustments for :		
Interest income	-12.29	-12.97
Gain/Loss on sale or disposal of Property, Plant and Equipment [Net]	-	-6.80
Interest expense	3.25	4.29
Depreciation and Amortization Expense	51.04	44.98
Operating Profit Before Working Capital Changes	102.38	84.96
Increase / (Decrease) in Trade Payables	-35.54	28.16
Increase / (Decrease) in Other liabilities	-31.01	24.26
Increase / (Decrease) in Short Term Provisions	-9.53	15.69
Increase / (Decrease) in Other Long Term Liabilities/ Provisions	5.46	0.43
Decrease / (Increase) in Inventories	-20.18	-24.45
Decrease / (Increase) in Trade Receivables	-30.58	-94.31
Decrease / (Increase) in loans and advances	3.62	-12.40
Decrease / (Increase) in Other assets	-43.58	-94.26
Decrease / (Increase) in Other Non-Current assets	-9.18	-
Cash generated from / (used in) Operations	-68.15	-71.91
Income taxes paid	-21.40	-15.96
Net Cash generated from / (used in) Operating Activities	-89.55	-87.87
B. CASH FLOW FROM INVESTING ACTIVITIES		
Purchase of Property, Plant and Equipment and Intangible Assets	-57.08	-116.46
Sale proceeds of Property, Plant and Equipment and Intangible Assets	2.00	30.55
Purchase of Non-current investments	-1.20	-
Interest received	12.29	12.97
Net Cash generated from / (used in) Investing Activities	-43.99	-72.93
C. CASH FLOW FROM FINANCING ACTIVITIES		
Proceeds from issue of Share capital	-	488.75
Proceeds from Long-Term Borrowings	35.76	-28.59
Repayment of Short-Term Borrowings	-	-57.72
Interest paid	-3.25	-4.29
Net Cash generated from / (used in) Financing Activities	32.52	398.15
Net Increase / (Decrease) In Cash and Cash Equivalents	-101.02	237.35
Cash and Cash Equivalents at the Beginning	307.48	70.13
Cash and Cash Equivalents at the End	206.46	307.48

This cash flow statement has been prepared as per 'Indirect Method' as prescribed by Accounting Standard-3 (revised) "Cash Flow Statements"

As per our report of even date

For Kale Malde & Co.
Chartered Accountants
FRN: 154422W




CA Alpesh Malde
Partner
Membership No: 138034
Date: 28/05/2026
Place: Dombivli

ICAI UDIN:26138034CRITYXP4415



For and on behalf of the Board of Directors of
CLINITECH LABORATORY LIMITED


Jagdish Umakant Nayak
Chairman & Managing Director
DIN : 00646672
Date: 28/05/2026
Place: Navi Mumbai



Notes to the Audited Standalone Financial Results:

1. The audited standalone Financial results were reviewed by the Audit Committee and taken on record by the Board of Directors at their meeting held on 28th May, 2026.
2. As required under Regulation 33 of SEBI (LODR) Regulations, 2015, the Statutory Auditors have issued Reports on the audited financial results for the half-year ended and financial year ended 31st March, 2026. These results were also approved by the Audit Committee and the Board of Directors at their meeting held on 28th May, 2026.
3. Earnings per Share (EPS) has been computed in accordance with Accounting Standard (AS) 20 – *Earnings Per Share*.
4. The Company is engaged in a single segment of Pathology and healthcare business. Therefore, segment-wise reporting as per Accounting Standard (AS) 17 – *Segment Reporting* is not applicable.
5. As per MCA Notification dated 16th February 2015, companies listed on the SME Exchange, as referred to in Chapter XB of SEBI (ICDR) Regulations, 2009, are exempt from the mandatory adoption of Ind-AS. Accordingly, the Company has not adopted Ind-AS for preparation of these Standalone Financial results.
6. Figures of the previous period/year have been regrouped or reclassified wherever necessary to make them comparable with the current period's figures.
7. The Standalone Financial results are available on the website of the Company and the website of the stock exchange where the shares of the company are listed.



Independent Auditor's Report on Half yearly and Yearly Consolidated Financial Results of the CLINITECH LABORATORY LIMITED Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

INDEPENDENT AUDITOR'S REPORT

To,
The Board of Directors of
CLINITECH LABORATORY LIMITED

Opinion

We have audited the accompanying half yearly and yearly consolidated financial results ('the Statement') of **CLINITECH LABORATORY LIMITED** ('the Company') for the half year and year ended on 31st March, 2026 and year to date results for the period from April 01, 2025 to March 31, 2026 prepared and being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended (The 'Listing Regulations').

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid Consolidated Financial statements

- a) are presented in accordance with the requirements of Regulation 33 of the Regulations; and
- b) give the information required by the Companies Act, 2013 ("the Act") in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2026, and net profit and other financial information for the year ended on 31st March, 2026.

Basis for Opinion

We conducted our audit of the Consolidated Financial statements in accordance with the Standards on Auditing ("SAs") specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Consolidated Financial statements section of our report.

We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the Consolidated Financial statements under the



provisions of the Companies Act, 2013 and the Rules there under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Consolidated Financial statements

Management's Responsibility for Consolidated Financial Results

This statement, is the responsibility of the Company's Management and approved by the Board of Directors has been compiled the basis of Consolidated Financial statements for the year ended 31 March, 2026. The Company's Board of Directors are responsible for the preparation and presentation of the Financial Results that gives true and fair view of the net profit and other comprehensive income and other financial information in accordance with the accounting principles generally accepted in India, including the accounting Standards specified under section 133 of the Act and in compliance with Regulation 33 of the listing Regulations.

This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Consolidated Financial statements, The Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Consolidated Financial Results

Our objectives are to obtain reasonable assurance about whether the financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will



always detect a material misstatement when it exists.

Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. But not for the purpose of expressing an opinion on the effectiveness of such controls.
- Evaluate the appropriateness and reasonableness of disclosures made by Board of Directors in the term of the requirement specified under Regulation 33 of the Listing Regulation.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Consolidated Financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial Results, including the disclosures and whether the financial Results represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the Financial Results of the Company to Express an Opinion on the Financial Results.

Materiality is the magnitude of misstatements in the Financial Results that, individually or in aggregate, makes it probable that the economic decisions of are reasonably knowledgeable user of the Financial Results may be influenced. We consider



quantitative materiality and qualitative factors in –

1. Planning the scope of our audit work and in evaluating the results of our work; and
2. To evaluate the effect of any identified misstatements in the Financial Results.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matters

The Annual Consolidated Financial Results dealt with by this report have been prepared for the express purpose of filing with Stock Exchanges. These results are based on and should be read with the audited Consolidated Financial statements of the Company for the year ended 31st March 2026 on which we issued an unmodified audit opinion.

The result includes the results of the half year ended 31st March, 2026 being the balancing figure between the audited figure in respect of the full financial year ended 31st March, 2026 and the unaudited year –to-date figures up to the first half ended on 30th Sep, 2025 of the current financial year which were subject to a limited review by us, as required under the Listing Regulations.

For Kale Malde & Co.

Chartered Accountants
FRN: 154422W


CA. Alpesh Malde
Partner

Membership No. 138034

Place: Dombivli

Date: 28/05/2026

ICAI UDIN: **26138034ZHMRGH2385**



CLINITECH LABORATORY LIMITED

CIN : L85195MH2010PLC201078

Audited Consolidated Balance Sheet as at 31st March, 2026

All amounts in Lakhs, unless otherwise stated

Particulars	As at March 31, 2026	As at March 31, 2025
I. EQUITY AND LIABILITIES		
Shareholders' funds		
Share capital	228.24	228.24
Reserves and Surplus	696.59	654.80
Minority Interest	0.49	-
	925.32	883.04
Non-current liabilities		
Long-Term Borrowings	53.75	-
Long-Term Provisions	25.34	19.87
	79.09	19.87
Current liabilities		
Trade Payables		
total outstanding dues of micro and small enterprises	27.06	69.74
total outstanding dues of creditors other than micro and small enterprises	21.30	5.76
Other current liabilities	43.49	74.45
Short-Term Provisions	21.61	31.14
	113.46	181.09
TOTAL EQUITY AND LIABILITIES	1117.87	1084.00
II. ASSETS		
Non-current assets		
Property, Plant and Equipment and Intangible Assets		
Property, Plant and Equipment	214.35	211.92
Capital work-in-progress	25.51	-
Intangible assets	3.99	0.39
Intangible Assets under development	99.12	101.12
Non-current investments	7.29	7.29
Deferred Tax Assets (Net)	19.92	16.65
Other Non-Current Assets	10.23	-
	380.41	337.37
Current assets		
Inventories	73.05	52.87
Trade Receivables	185.47	154.10
Cash and Cash Equivalents	211.22	307.48
Short-term loans and advances	65.01	73.15
Other current assets	202.71	159.03
	737.46	746.63
TOTAL ASSETS	1117.87	1084.00

As per our report of even date

**For Kale Malde & Co.
Chartered Accountants**

FRN: 154422W


**CA. Alpesh Malde
Partner**

Membership No: 138034

Date: 28/05/2026

Place: Dombivli

ICAI UDIN: 26138034ZHMRGH2385



For and on behalf of the Board of Directors of
CLINITECH LABORATORY LIMITED


**Jagdish Umakant Nayak
Chairman & Managing Director**
DIN : 00546672
Date: 28/05/2026
Place: Navi Mumbai



CLINITECH LABORATORY LIMITED

CIN : L85195MH2010PLC201078


Audited Consolidated Financial Results for the Half Year and Year ended 31st March, 2026

All amounts in INR Lakhs, unless otherwise stated

Particulars	Half year Ended on			Year Ended on	
	31-Mar-26	30-Sep-25	31-Mar-25	31-Mar-26	31-Mar-25
	Audited	Unaudited	Audited	Audited	Audited
A] REVENUE					
Revenue from operations	441.10	508.02	415.89	949.12	823.49
Other income	7.81	11.00	17.38	18.81	22.77
B] Total Income	448.91	519.02	433.27	967.93	846.26
C] Expenses:					
Cost of materials consumed	88.42	137.76	75.23	226.18	155.93
Laboratory Testing Charges	14.21	17.43	14.38	31.64	27.33
Employee benefits expense	151.18	157.18	145.29	308.36	286.14
Finance costs	2.19	4.74	1.79	6.93	5.51
Depreciation and Amortization Expense	25.99	25.05	13.76	51.04	44.98
Other Expenses	142.38	141.78	153.30	284.17	270.90
D] Total expenses	424.37	483.94	403.75	908.32	790.79
E] Profit before tax	24.54	35.08	29.52	59.61	55.47
F] Tax expense:					
(1) Current tax	11.55	4.68	11.31	16.23	15.96
(2) Excess/(Short) Provision of Income tax	5.17	-	-	5.17	-
(3) Deferred tax	-3.64	0.37	0.84	-3.27	0.04
G] Total Tax Expenses	13.08	5.05	12.15	18.13	16.00
H] Profit After Tax before Minority Interest [E - G]	11.46	30.03	17.37	41.48	39.47
Less/(Add): Minority Interest share in Profit/(Loss) of Subsidiaries	0.31	-	-	0.31	-
Profit for the year attributable to owners of the Parent Company	11.77	30.03	17.37	41.79	39.47
Earning per equity share:					
Face value per equity shares Rs.10/- fully paid up.					
(1) Basic	0.52	1.32	0.83	1.83	1.90
(2) Diluted	0.52	1.32	0.83	1.83	1.90

As per our report of even date

For KALE MALDE & CO.
Chartered Accountants
ICAI F.R.No. 154422W


CA. Alpesh Malde
Partner

Membership No: 138034
Date: 28/05/2026
Place: Dombivli
ICAI UDIN: 26138034ZHMRGH2385



For & On Behalf of the Board
CLINITECH LABORATORY LIMITED


Jagdish Nayak
Chairman and Managing Director
DIN : 00646672
Date: 28/05/2026
Place: Navi Mumbai



CLINITECH LABORATORY LIMITED

CIN : L85195MH2010PLC201078

Audited Consolidated Statement of Cash Flows for the year ended 31st March, 2026

All amounts in Lakhs, unless otherwise stated

Particulars	Year ended March 31, 2026	Year ended March 31, 2025
A. CASH FLOW FROM OPERATING ACTIVITIES		
Profit before tax	59.62	55.47
Adjustments for :		
Interest income	-12.29	-12.97
Gain/Loss on sale or disposal of Property, Plant and Equipment [Net]	0.00	-6.80
Interest expense	3.25	4.29
Depreciation and Amortization Expense	51.04	44.98
Operating Profit Before Working Capital Changes	101.61	84.96
Increase / (Decrease) in Trade Payables	-27.14	28.16
Increase / (Decrease) in Other liabilities	-30.96	24.26
Increase / (Decrease) in Short Term Provisions	-9.53	15.69
Increase / (Decrease) in Other Long Term Liabilities/ Provisions	5.46	0.43
Decrease / (Increase) in Inventories	-20.18	-24.45
Decrease / (Increase) in Trade Receivables	-31.37	-94.31
Decrease / (Increase) in loans and advances	8.14	-12.40
Decrease / (Increase) in Other assets	-43.68	-94.26
Decrease / (Increase) in Other Non - Current assets	-10.23	-
Cash generated from / (used in) Operations	-57.86	-71.91
Income taxes paid	-21.40	-15.96
Net Cash generated from / (used in) Operating Activities	-79.26	-87.87
B. CASH FLOW FROM INVESTING ACTIVITIES		
Purchase of Property, Plant and Equipment and Intangible Assets	-82.58	-116.46
Sale proceeds of Property, Plant and Equipment and Intangible Assets	2.00	30.55
Purchase of Non-current investments	-	-
Interest received	12.29	12.97
Net Cash generated from / (used in) Investing Activities	-68.29	-72.93
C. CASH FLOW FROM FINANCING ACTIVITIES		
Proceeds from issue of Share capital	0.80	488.75
Proceeds from Long-Term Borrowings	53.75	-28.59
Repayment of Short-Term Borrowings	-	-57.72
Interest paid	-3.25	-4.29
Net Cash generated from / (used in) Financing Activities	51.30	398.15
Net Increase / (Decrease) In Cash and Cash Equivalents	-96.26	237.35
Cash and Cash Equivalents at the Beginning	307.48	70.13
Cash and Cash Equivalents at the End	211.22	307.48

This cash flow statement has been prepared as per 'Indirect Method' as prescribed by Accounting Standard-3 (revised) "Cash Flow Statements"

As per our report of even date

For Kale Malde & Co.
Chartered Accountants
FRN: 154422W

CA. Alpesh Malde
Partner
Membership No: 138034
Date: 28/05/2026
Place: Dombivli
ICAI UDIN: 26138034ZHMRGH2385



For and on behalf of the Board of Directors of
CLINITECH LABORATORY LIMITED

Jagdish Umakant Nayak
Chairman & Managing Director
DIN : 00646672
Date: 28/05/2026
Place: Navi Mumbai



Notes to the Audited Consolidated Financial Results:

1. The audited Consolidated Financial results were reviewed by the Audit Committee and taken on record by the Board of Directors at their meeting held on 28th May, 2026.
2. As required under Regulation 33 of SEBI (LODR) Regulations, 2015, the Statutory Auditors have issued Reports on the audited financial results for the half-year ended and yearly 31st March, 2026 . These results were also approved by the Audit Committee and the Board of Directors at their meeting held on 28th May, 2026.
3. The consolidated financial results include the financial performance of the holding company and its subsidiary, in accordance with Accounting Standard (AS) 21 – Consolidated Financial Statements, as notified under the Companies (Accounting Standards) Rules, 2006.
4. Earnings per Share (EPS) has been computed in accordance with Accounting Standard (AS) 20 – *Earnings Per Share*.
5. The Holding Company is primarily engaged in the single segment of pathology and healthcare business. Other business activities carried out by the subsidiaries are not material for separate reportable segment disclosure in accordance with Accounting Standard (AS) 17 – ‘Segment Reporting’. Accordingly, separate segment information has not been furnished.
6. As per MCA Notification dated 16th February 2015, companies listed on the SME Exchange, as referred to in Chapter XB of SEBI (ICDR) Regulations, 2009, are exempt from the mandatory adoption of Ind-AS. Accordingly, the Company has not adopted Ind-AS for preparation of these Consolidated Financial results.
7. Figures of the previous period/year have been regrouped or reclassified wherever necessary to make them comparable with the current period's figures.
8. The Consolidated Financial results are available on the website of the Company and the website of the stock exchange where the shares of the company are listed.



To,
Clinitech Laboratory Limited
AL 1 545/546, sec 16 Airoli,
Opp. Smt. Radhikabai Meghe Vidyalaya,
Navi Mumbai - 400 708

Sub: Certificate of Utilization of IPO Funds for the period ending on 31st
March 2026

Management's responsibility for the Statement:

1. The preparation of the information in terms of the requirements of Generally Accepted Accounting principle (GAAP) is the responsibility of the Management of M/s Clinitech Laboratory Limited including the preparation and maintenance of all accounting and other relevant supporting record. This responsibility includes the design, implementation and maintenance of internal control relevant to the preparation and presentation of the statement and applying an appropriate basis of preparation; and making estimates that are reasonable in the circumstances.

Practitioner's responsibility:

2. Pursuant to the requirements of the requirements for certification of fund utilization as stipulated by SEBI and NSE, as per applicable regulations, our responsibility to examine the books of accounts and other relevant documents / records of the applicant and to provide a reasonable assurance that the information declared in the Statement are in accordance with the books of accounts maintained.
3. To conduct our examination of the Statement in accordance with the Guidance Note on Reports or Certificates for Special Purposes (Revised 2016) issued by the Institute of Chartered Accountants of India. The Guidance Note requires that we comply with the ethical requirements of the Code of Ethics issued by the Institute of Chartered Accountants of India.
4. To comply with the relevant applicable requirements of the Standard on Quality Control (SQC) 1, Quality Control for Firms that Perform Audits and Reviews of Historical Financial Information, and Other Assurance and Related Services Engagements.



Opinion

1. We have conducted our examination in accordance with the Guidance Note on Reports or Certificates for Special Purposes (Revised 2016) issued by the Institute of Chartered Accountants of India. The Guidance Note requires that we comply with the ethical requirements of the Code of Ethics issued by the Institute of Chartered Accountants of India.
2. This certificate has been issued the request of the company and based on the information and documents provided by the management and is meant solely for the purpose of bank finance as per attached Annexure.

Restriction on Use

This certificate is addressed and provided to the verify the statutory records and books accounts to Verify the utilization of IPO funds aligns with the purposes specified in the prospectus details given in Attached annexure. This certificate solely for the purpose of submission to BSE and should not be used by any other person or for any other purpose. Accordingly, we do not accept or assume any liability or duty of care for any other purpose or to any other person to whom this certificate is shown or into whose hands it may come without our prior consent in writing.

For M/s. Kale Malde & Co.
Chartered Accountants
FRN - 0154422W



CA Alpesh Malde
M. no. 138034
Date: 28/05/2026
Place: Dombivli
UDIN: 26138034KVOOEV9004



Annexure A

We have examined the books of account and other relevant records/documents maintained by the company in connection with the utilization of proceeds of the Initial Public Offering (IPO) as stated in the Offer Document for issuing 6,02,400 equity shares of ₹10/- each at a premium of ₹86/- per share total Amounting to Rs. 5,78,30,400/-

As of 31st march, 2026 the details of funds raised, and their application are as follows:

(Amount in Lakhs)

Sr. No.	Object as disclosed in the Offer Document	Amount disclosed in the Offer Document	Actual Utilised Amount	Unutilised Amount	Remarks
1	Expansion of Diagnostic Business	498.67	448.67	50.00	
2	General Corporate Purposes	41.33	41.33	0.00	
3	Issue Related Expenses	38.30	38.30	0.00	
	Total	578.30	528.30	50.00	

We certify that:

- The company has partially applied the IPO proceeds for the disclosed purposes as of 31st march, 2026.
- The unutilized balance remains held in short-term deposits and bank balances, as reflected in the financial statements.

This certificate is issued as per the guidance provided in the relevant ICAI pronouncements for a special-purpose certificate and is intended solely for your information.

For M/s. Kale Malde & Co.
Chartered Accountants
FRN - 0154422W

CA Alpesh Malde
M. no. 138034
Date: 28/05/2026
Place: Dombivli
UDIN: 26138034KVOOEV9004

